Novartis unveiled today new data on its promising pipeline amid plans for multiple new product approvals and launches over the next two years. Many of these anticipated approvals are for potentially best-in-class medicines that would advance treatment standards for patients with hypertension, diabetes, cancer and other diseases.
King Pharmaceuticals, Inc. (NYSE: KG) and Depomed, Inc. (NASDAQ: DEPO) today announced the launch of a new program that will provide support for patients with diabetes who are receiving treatment with Glumetza (metformin hydrochloride extended-release tablets), a new once-daily extended-release metformin formulation that features AcuForm drug-delivery technology.
People who suffer from job burnout may be prone to developing type 2 diabetes, according to a study of 677 mostly male middle-aged Israeli workers, published in the journal Psychosomatic Medicine.
Hearty feasts and couch-potato marathons are holiday traditions, but UT Southwestern Medical Center experts warn that packing on pounds and not exercising could be deadly for the 6 million Americans who have diabetes and don’t even know it.
Asian Indian men are at increased risk to develop type 2 diabetes mellitus because of chronic liver disease rather than obesity, Yale School of Medicine researchers report in the November 13 issue of the Proceedings of the National Academy of Sciences.
More than 20 million Americans suffer from diabetes, a serious, chronic illness. Now, during American Diabetes Month, everyone has an opportunity to make an impact in the fight against the disease, at no cost, with just a click of the mouse. For each visitor who clicks at www.Click4Diabetes.com, a donation will be made to the American Diabetes Association (ADA), the nation’s leading nonprofit health organization providing diabetes research, information and advocacy.
Rosa?s Story, an audio-novella from the Joslin Diabetes Center Latino Diabetes Initiative, uses the art of storytelling to educate listeners about the challenges of diabetes faced by the Hispanic/Latino population. The first-person accounts of a fictitious Latino woman with type 2 diabetes, and a teenager with pre-diabetes, are told in the new educational package. Designed for Spanish-speaking Latinos with diabetes and their families, the three-CD set is being launched on Nov. 14, World Diabetes Day, a day set aside by the International Diabetes Federation (IDF) and the World Health Organization to increase public awareness of the global diabetes epidemic.
Another late-breaker presented here was the appropriately named CHICAGO Study, in which 462 patients with type 2 diabetes were randomly selected at Chicago heart clinics to receive treatment with pioglitazone or with glimepriride.
Researchers today presented data showing that ACTOS (pioglitazone HCl) halted the progression of atherosclerosis as measured by carotid intima-media thickness (CIMT) in patients with type 2 diabetes. Results from the clinical trial, CHICAGO (Carotid intima-media thickness in Atherosclerosis using pioglitazone), are part of a late-breaker presentation at the American Heart Association’s Scientific Sessions 2006, coincidentally being held in Chicago, and coincide with an early online issue of the Journal of the American Medical Association.
A drug commonly used to increase the body’s sensitivity to insulin may slow the progression of cardiovascular disease in patients with type 2 diabetes, according to a study at the University of Illinois at Chicago College of Medicine.